Bruker Corporation (Nasdaq: BRKR) announced today that it will unveil significant advancements in spatial biology at the 2025 ...

The costs of genomic sequencing have fallen very rapidly for the past decade and will continue to do so. As it becomes less ...

Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth ...